[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571211":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":41,"locations":49,"responsibleParty":105,"collaborators":10,"id":109,"slug":10,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":10,"studyType":122,"phases":10,"briefSummary":123,"conditions":124,"keywords":133,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Dysplasia Diagnostics Limited","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer Patients (Phase 1)",null,"This arm will include 3,500 individuals with confirmed diagnoses of common cancers such as Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, and Pancreatic Cancer.",[13],"Diagnostic Test: DiNanoQ: A multi-cancer early detection (MCED) blood test",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy Individuals","This arm will consist of 1,500 age- and sex-matched cancer-free individuals serving as controls.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cancer Patients Undergoing Treatment","This cohort will include 1,000 patients diagnosed with Hepatocellular Carcinoma (HCC) or Non-Small Cell Lung Cancer (NSCLC) across stages I to IV who are about to commence standard cancer therapy.",[13,22],"Other: DiNanoTrack: Therapeutic Response Monitoring Blood Test",[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DIAGNOSTIC_TEST","DiNanoQ: A multi-cancer early detection (MCED) blood test","Procedure: Participants will undergo a single blood draw at baseline.\n\nSample Analysis:\n\nPlatelet Isolation: Platelets will be extracted from the collected blood samples.\n\nRNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.",[9,19,15],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"OTHER","DiNanoTrack: Therapeutic Response Monitoring Blood Test","Procedures:\n\nBlood Sample Collection: Participants will have blood samples drawn at three time points:\n\nBaseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.\n\nSample Analysis:\n\nPlatelet and Immune Cell Isolation:\n\nPlatelets: Extracted from each blood sample to continue monitoring RNA profiles.\n\nImmune Cells: Separated from the blood samples to analyse immune response to therapy.\n\nRNA Analysis:\n\nPlatelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.\n\nImmune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.\n\nData Correlation:\n\nTherapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance.",[19],[35,38],{"name":36,"affiliation":5,"role":37},"Solomon Rotimi, PhD","STUDY_DIRECTOR",{"name":39,"affiliation":5,"role":40},"Javier Toledo, Medical Degree","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":10,"email":45},"CONTACT","+44 (0)1223 496000","research@dysplasiadx.com",{"name":47,"role":43,"phone":44,"phoneExt":10,"email":48},"Osagie Izuogu, PhD","info@dysplasiadx.com",[50,62,81,93],{"facility":51,"status":52,"city":53,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":10},"Various Cancer Centres","ACTIVE_NOT_RECRUITING","Rosario","Argentina","AR",{"type":57,"coordinates":58},"Point",[59,60],-60.63932,-32.94682,{"lat":60,"lon":59},{"facility":63,"status":64,"city":65,"state":10,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"NSIA- Lagos University Teaching Hospital Cancer Centre","RECRUITING","Lagos","Nigeria","NG",{"type":57,"coordinates":69},[70,71],3.39467,6.45407,{"lat":71,"lon":70},[74,78],{"name":75,"role":43,"phone":76,"phoneExt":10,"email":77},"Adewumi Alabi, Oncology","+2348052843206","aalabi@nlcc.ng",{"name":79,"role":43,"phone":10,"phoneExt":10,"email":80},"Solomon Rotimi, Ph.D","solomon@dysplasiadx.com",{"facility":82,"status":83,"city":84,"state":10,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"Babraham Research Institute","ENROLLING_BY_INVITATION","Cambridge","CB22 3AT","United Kingdom","UK",{"type":57,"coordinates":89},[90,91],0.11667,52.2,{"lat":91,"lon":90},{"facility":5,"status":64,"city":94,"state":10,"zip":95,"country":86,"countryCode":87,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"London","W1W 7LT",{"type":57,"coordinates":97},[98,99],-0.12574,51.50853,{"lat":99,"lon":98},[102],{"name":103,"role":43,"phone":104,"phoneExt":10,"email":45},"Chief Medical Officer, Medical","+447494946013",{"type":106,"investigatorFullName":107,"investigatorTitle":108,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Javier Toledo","Chief Medical Officer","100571211",false,"NCT06717295","The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","CCANED-CIPHER","Phase 1 (Common Cancer Early Detection - CCANED)\n\nInclusion Criteria:\n\n* Age: Adults aged 40 years or older.\n* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.\n\nExclusion Criteria:\n\n* Currently pregnant.\n* Presence of any active infectious diseases.\n* Use of anticoagulant or antiplatelet drugs within the past 2 weeks.\n* Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.\n\nPhase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)\n\nInclusion Criteria:\n\n* Adults aged 40 years or older.\n* Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)\n* Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).\n\nExclusion Criteria:\n\n* Presence of another malignancy unless it has been in remission for at least 5 years.\n* Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.",true,"ALL","40 Years","75 Years",{"count":120,"type":121},6000,"ESTIMATED","OBSERVATIONAL","The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.",[125,126,127,128,129,130,131,132],"Brest Cancer","Lung Cancer (NSCLC)","Pancreatic Cancer, Adult","Prostate Cancers","Ovarian Cancer","Colorectal Cancer","Glioblastoma (GBM)","Liver Carcinoma",[134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149],"cancer screening","Liquid Biopsy","AI-based Diagnostics","Early Cancer Detection","Circulating Tumor DNA (ctDNA)","RNA Profiling","Biomarker","Precision Medicine","Oncology","Health Data Analysis","Platelets","treatment response","RNA","CircRNA","Splicing","Cancer","2025-12-29",{"date":152,"type":153},"2026-01-02","ACTUAL",{"date":155,"type":153},"2025-12-20",{"date":157,"type":121},"2028-08-01",{"name":107,"class":6},4]